BACKGROUND AIMS: The discovery of unrestricted somatic stem cells (USSC), a non-hematopoietic stem cell population, brought cord blood (CB) to the attention of regenerative medicine for defining more protocols for non-hematopoietic indications. We demonstrate that a reliable and reproducible method for good manufacturing practice (GMP)-conforming generation of USSC is possible that fulfils safety requirements as well as criteria for clinical applications, such as adherence of strict regulations on cell isolation and expansion. METHODS: In order to maintain GMP conformity, the automated cell processing system Sepax (Biosafe) was implemented for mononucleated cell (MNC) separation from fresh CB. After USSC generation, clinical-scale expansion was achieved by multi-layered CellSTACKs (Costar/Corning). Infectious disease markers, pyrogen and endotoxin levels, immunophenotype, potency, genetic stability and sterility of the cell product were evaluated. RESULTS: The MNC isolation and cell cultivation methods used led to safe and reproducible GMP-conforming USSC production while maintaining somatic stem cell character. CONCLUSIONS: Together with implemented in-process controls guaranteeing contamination-free products with adult stem cell character, USSC produced as suggested here may serve as a universal allogeneic stem cell source for future cell treatment and clinical settings.
BACKGROUND AIMS: The discovery of unrestricted somatic stem cells (USSC), a non-hematopoietic stem cell population, brought cord blood (CB) to the attention of regenerative medicine for defining more protocols for non-hematopoietic indications. We demonstrate that a reliable and reproducible method for good manufacturing practice (GMP)-conforming generation of USSC is possible that fulfils safety requirements as well as criteria for clinical applications, such as adherence of strict regulations on cell isolation and expansion. METHODS: In order to maintain GMP conformity, the automated cell processing system Sepax (Biosafe) was implemented for mononucleated cell (MNC) separation from fresh CB. After USSC generation, clinical-scale expansion was achieved by multi-layered CellSTACKs (Costar/Corning). Infectious disease markers, pyrogen and endotoxin levels, immunophenotype, potency, genetic stability and sterility of the cell product were evaluated. RESULTS: The MNC isolation and cell cultivation methods used led to safe and reproducible GMP-conforming USSC production while maintaining somatic stem cell character. CONCLUSIONS: Together with implemented in-process controls guaranteeing contamination-free products with adult stem cell character, USSC produced as suggested here may serve as a universal allogeneic stem cell source for future cell treatment and clinical settings.
Authors: Jessica Schira; Heiner Falkenberg; Marion Hendricks; Daniel M Waldera-Lupa; Gesine Kögler; Helmut E Meyer; Hans Werner Müller; Kai Stühler Journal: Mol Cell Proteomics Date: 2015-07-16 Impact factor: 5.911
Authors: Jan Spanholtz; Frank Preijers; Marleen Tordoir; Carel Trilsbeek; Jos Paardekooper; Theo de Witte; Nicolaas Schaap; Harry Dolstra Journal: PLoS One Date: 2011-06-16 Impact factor: 3.240
Authors: Govindaiah Vinukonda; Yanling Liao; Furong Hu; Larisa Ivanova; Deepti Purohit; Dina A Finkel; Priyadarshani Giri; Lakshmipramoda Bapatla; Shetal Shah; Muhammed T Zia; Karen Hussein; Mitchell S Cairo; Edmund F La Gamma Journal: Stem Cells Transl Med Date: 2019-07-19 Impact factor: 6.940
Authors: Jessica Schira-Heinen; Agathe Czapla; Marion Hendricks; Andreas Kloetgen; Wasco Wruck; James Adjaye; Gesine Kögler; Hans Werner Müller; Kai Stühler; Hans-Ingo Trompeter Journal: Sci Rep Date: 2020-02-24 Impact factor: 4.379